Senior Director, Commercial Development
Molecular Insight Pharmaceuticals
Developed & led the commercial vision for orphan oncology candidates in phase II to ensure “launch readiness”.
·Branding – Developed U.S. and E.U. brand elements including positioning, targeted messaging, logo, and taglines that resulted in the final brand for Azedra™ (phase 2 candidate for Pheochromocytoma and Neuroblastoma), ahead of schedule.
·Medical Education – Managed and worked closely with Agency resulting in the following:
▪ 2 comprehensive Publication Plans - (a) Azedra™ and (b) Zemiva™ (for cardiology), to be used as a roadmap through 2010.
▪ 5 Continuing Medical Education Symposia
▪ 8 Executive Advisory Boards comprised of Key Opinion Leaders (4 oncology & 4 cardiology)
▪ Slide kit for Medical Science Liaison use
·Patient Advocacy - Developed “full-partnerships” with 3 oncology focused patient advocacy groups. Molecular Insight was featured in multiple outreach programs resulting in increased awareness of Azedra™.
·KOL development - built relationships and brought market insight to the product development team.
·Coordinated strategic planning process for Sales Force development and Medical Science Liaisons.
·Worked on comprehensive marketing plan for rapidly increasing patient enrollment in phase 2a clinical trial for Azedra™, under a Special Protocol Assessment, with Fast Track Designation, and Orphan Drug Status.
·Developed forecasts and pricing models for the United States & Europe.
·Directed the development and approval of all marketing collateral used at International congresses.
·Lead due diligence on 10 portfolio expansion opportunities leading to multiple licensing transactions, most notably with Novartis for Onalta™ (Carcinoid), and Bayer Schering for Solazed™ (Melanoma).
- Promoted from Director to Senior Director in July 2008.